GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eisai Co Ltd (OTCPK:ESALF) » Definitions » E10

Eisai Co (Eisai Co) E10 : $5.27 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Eisai Co E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Eisai Co's adjusted earnings per share data for the three months ended in Dec. 2023 was $0.145. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $5.27 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Eisai Co's average E10 Growth Rate was -1.60% per year. During the past 3 years, the average E10 Growth Rate was -1.80% per year. During the past 5 years, the average E10 Growth Rate was 2.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Eisai Co was 7.80% per year. The lowest was -1.80% per year. And the median was 3.80% per year.

As of today (2024-04-29), Eisai Co's current stock price is $40.005. Eisai Co's E10 for the quarter that ended in Dec. 2023 was $5.27. Eisai Co's Shiller PE Ratio of today is 7.59.

During the past 13 years, the highest Shiller PE Ratio of Eisai Co was 16.55. The lowest was 6.49. And the median was 9.90.


Eisai Co E10 Historical Data

The historical data trend for Eisai Co's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eisai Co E10 Chart

Eisai Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.66 6.50 7.46 6.45 5.88

Eisai Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.62 5.88 5.43 4.96 5.27

Competitive Comparison of Eisai Co's E10

For the Drug Manufacturers - Specialty & Generic subindustry, Eisai Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eisai Co's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eisai Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Eisai Co's Shiller PE Ratio falls into.



Eisai Co E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Eisai Co's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.145/106.8000*106.8000
=0.145

Current CPI (Dec. 2023) = 106.8000.

Eisai Co Quarterly Data

per share eps CPI Adj_EPS
201403 1.436 95.700 1.603
201406 0.780 98.000 0.850
201409 0.617 98.500 0.669
201412 3.083 97.900 3.363
201503 0.761 97.900 0.830
201506 0.615 98.400 0.668
201509 0.649 98.500 0.704
201512 3.133 98.100 3.411
201603 2.054 97.900 2.241
201606 2.617 98.100 2.849
201609 1.121 98.000 1.222
201612 1.265 98.400 1.373
201703 0.116 98.100 0.126
201706 1.235 98.500 1.339
201709 1.136 98.800 1.228
201712 1.148 99.400 1.233
201803 3.125 99.200 3.364
201806 1.561 99.200 1.681
201809 2.532 99.900 2.707
201812 0.911 99.700 0.976
201903 2.939 99.700 3.148
201906 2.798 99.800 2.994
201909 0.691 100.100 0.737
201912 5.916 100.500 6.287
202003 6.288 100.300 6.695
202006 3.168 99.900 3.387
202009 0.181 99.900 0.194
202012 2.604 99.300 2.801
202103 -0.414 99.900 -0.443
202106 5.335 99.500 5.726
202109 0.498 100.100 0.531
202112 1.735 100.100 1.851
202203 -0.360 101.100 -0.380
202206 0.700 101.800 0.734
202209 0.087 103.100 0.090
202212 0.223 104.100 0.229
202303 0.426 104.400 0.436
202306 0.502 105.200 0.510
202309 0.133 106.200 0.134
202312 0.145 106.800 0.145

Add all the adjusted EPS together and divide 10 will get our e10.


Eisai Co  (OTCPK:ESALF) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Eisai Co's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=40.005/5.27
=7.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Eisai Co was 16.55. The lowest was 6.49. And the median was 9.90.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Eisai Co E10 Related Terms

Thank you for viewing the detailed overview of Eisai Co's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Eisai Co (Eisai Co) Business Description

Traded in Other Exchanges
Address
4-6-10 Koishikawa, Bunkyo-ku, Tokyo, JPN, 112-8088
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.